Comparative evaluation of three-dimensional Gd-EOB-DTPA-enhanced MR fusion imaging with CT fusion imaging in the assessment of treatment effect of radiofrequency ablation of hepatocellular carcinoma

Abdominal Imaging

Volumn 40, Issue 1, 2015, Pages 102-111

  Makino, Yuki ^a   Imai, Yasuharu ^a   Igura, Takumi ^a   Hori, Masatoshi ^b   Fukuda, Kazuto ^a   Sawai, Yoshiyuki ^a   Kogita, Sachiyo ^a   Fujita, Norihiko ^a   Takehara, Tetsuo ^b   Murakami, Takamichi ^c  

^a IKEDA MUNICIPAL HOSPITAL   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KINKI UNIVERSITY   (Japan)

Author keywords

Ablative margin; Fusion imaging; Gd EOB DTPA; Hepatocellular carcinoma; Radiofrequency ablation

Indexed keywords

ANTINEOPLASTIC AGENT; GADOXETIC ACID; IODINATED POPPYSEED OIL; IOPAMIDOL; CONTRAST MEDIUM; GADOLINIUM PENTETATE;

ADULT; AGED; ARTICLE; CHEMOEMBOLIZATION; CLASSIFICATION; COMPARATIVE STUDY; COMPUTED TOMOGRAPHY SCANNER; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; IMAGE FUSION; IMAGE PROCESSING; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RADIOFREQUENCY ABLATION DEVICE; RETROSPECTIVE STUDY; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; THERAPY EFFECT; THREE DIMENSIONAL IMAGING; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; IMAGE ENHANCEMENT; LIVER; LIVER NEOPLASMS; MIDDLE AGED; MULTIMODAL IMAGING; PATHOLOGY; RADIOGRAPHY; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CONTRAST MEDIA; FEASIBILITY STUDIES; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; IMAGING, THREE-DIMENSIONAL; LIVER; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIMODAL IMAGING; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84942582964     PISSN: 09428925     EISSN: 14320509     Source Type: Journal    
DOI: 10.1007/s00261-014-0201-2     Document Type: Article

References (36)

1. Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52–60. doi:10.1055/s-0030-1247132
2. Bruix J, Sherman M, Llovet JM, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421–430
3. Fujioka C, Horiguchi J, Ishifuro M, et al. (2006) A feasibility study: evaluation of radiofrequency ablation therapy to hepatocellular carcinoma using image registration of preoperative and postoperative CT. Acad Radiol 13:986–994
4. Makino Y, Imai Y, Igura T, et al. (2013) Utility of CT fusion imaging for the evaluation of the ablative margin of radiofrequency ablation for hepatocellular carcinoma and the correlation to local tumor progression. Hepatol Res 43:950–958. doi:10.1111/hepr.12049
5. Niculescu G, Foran DJ, Nosher J (2007) Non-rigid registration of the liver in consecutive CT studies for assessment of tumor response to radiofrequency ablation. Conf Proc IEEE Eng Med Biol Soc 2007:856–859
6. Giesel FL, Mehndiratta A, Locklin J, et al. (2009) Image fusion using CT, MRI and PET for treatment planning, navigation and follow up in percutaneous RFA. Exp Oncol 31:106–114
7. Kim YS, Lee WJ, Rhim H, et al. (2010) The minimal ablative margin of radiofrequency ablation of hepatocellular carcinoma (>2 and <5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion. AJR Am J Roentgenol 195:758–765. doi:10.2214/AJR.09.2954
8. Kim KW, Lee JM, Klotz E, et al. (2011) Safety margin assessment after radiofrequency ablation of the liver using registration of preprocedure and postprocedure CT images. AJR Am J Roentgenol 196:W565–W572. doi:10.2214/AJR.10.5122
9. Tomonari A, Tsuji K, Yamazaki H, et al. (2013) Feasibility of fused imaging for the evaluation of radiofrequency ablative margin for hepatocellular carcinoma. Hepatol Res 43:728–734. doi:10.1111/hepr.12022
10. Passera K, Selvaggi S, Scaramuzza D, et al. (2013) Radiofrequency ablation of liver tumors: quantitative assessment of tumor coverage through CT image processing. BMC Med Imaging 13:3. doi:10.1186/1471-2342-13-3
11. Murakami T, Imai Y, Okada M, et al. (2011) Ultrasonography, computed tomography and magnetic resonance imaging of hepatocellular carcinoma: toward improved treatment decisions. Oncology 81(Suppl 1):86–99. doi:10.1159/000333267
12. Kogita S, Imai Y, Okada M, et al. (2010) Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma:correlation with histological grading and portal blood flow. Eur Radiol 20:2405–2413. doi:10.1007/s00330-010-1812-9
13. Sano K, Ichikawa T, Motosugi U, et al. (2011) Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MRI. Radiology 261:834–844. doi:10.1148/radiol.11101840
14. Onishi H, Kim T, Imai Y, et al. (2012) Hypervascular hepatocellular carcinomas: detection with gadoxetate disodium-enhanced MRI and multiphasic multidetector CT. Eur Radiol 22:845–854. doi:10.1007/s00330-011-2316-y
15. Okada M, Imai Y, Kim T, et al. (2010) Comparison of enhancement patterns of histologically confirmed hepatocellular carcinoma between gadoxetate- and ferucarbotran-enhanced magnetic resonance imaging. J Magn Reson Imaging 32:903–913. doi:10.1002/jmri.22333
16. Di Martino M, Marin D, Guerrisi A, et al. (2010) Intraindividual comparison of gadoxetate disodium-enhanced MRI and 64-section multidetector CT in the detection of hepatocellular carcinoma in patients with cirrhosis. Radiology 256:806–816. doi:10.1148/radiol.10091334
17. Makino Y, Imai Y, Ohama H, et al. (2013) Ultrasonography fusion imaging system increases the chance of radiofrequency ablation for hepatocellular carcinoma with poor conspicuity on conventional ultrasonography. Oncology 84(Suppl 1):44–50. doi:10.1159/000345889
18. Peng ZW, Zhang YJ, Liang HH, et al. (2012) Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial. Radiology 262:689–700. doi:10.1148/radiol.11110637
19. Peng ZW, Zhang YJ, Chen MS, et al. (2013) Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol 31:426–432. doi:10.1200/JCO.2012.42.9936
20. Bruix J, Sherman M, American Association for the Study of Liver Diseases (2011) Management of hepatocellular carcinoma: an update. Hepatology 53:1020–1022. doi:10.1002/hep.24199
21. de Lope CR, Tremosini S, Forner A, Reig M, Bruix J (2012) Management of HCC. J Hepatol 56(Suppl 1):S75–S87. doi:10.1016/S0168-8278(12)60009-9.22
22. Nakazawa T, Kokubu S, Shibuya A, et al. (2007) Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin. AJR Am J Roentgenol 188:480–488
23. Wood BJ, Kruecker J, Abi-Jaoudeh N, et al. (2010) Navigation systems for ablation. J Vasc Interv Radiol 21(8 Suppl):257–263. doi:10.1016/j.jvir.2010.05.003
24. Abi-Jaoudeh N, Mielekamp P, Noordhoek N, et al. (2012) Cone-beam computed tomography fusion and navigation for real-time positron emission tomography-guided biopsies and ablations: a feasibility study. J Vasc Interv Radiol 23:737–743. doi:10.1016/j.jvir.2012.02.006
25. Abi-Jaoudeh N, Kobeiter H, Xu S, Wood BJ (2013) Image fusion during vascular and nonvascular image-guided procedures. Tech Vasc Interv Radiol 16:168–176. doi:10.1053/j.tvir.2013.02.012
26. Carrillo A, Duerk JL, Lewin JS, Wilson DL (2000) Semiautomatic 3-D image registration as applied to interventional MRI liver cancer treatment. IEEE Trans Med Imaging 19:175–185
27. Dromain C, de Baere T, Elias D, et al. (2002) Hepatic tumors treated with percutaneous radio-frequency ablation: CT and MRI follow-up. Radiology 223:255–262
28. Bangard C, Stippel DL, Berg F, et al. (2008) Conspicuity of zones of ablation after radiofrequency ablation in porcine livers: comparison of an extracellular and an SPIO contrast agent. J Magn Reson Imaging 28:263–270. doi:10.1002/jmri.21423
29. Yoon JH, Lee EJ, Cha SS, et al. (2010) Comparison of gadoxetic acid-enhanced MRI versus four-phase multi-detector row computed tomography in assessing tumor regression after radiofrequency ablation in subjects with hepatocellular carcinomas. J Vasc Interv Radiol 21:348–356. doi:10.1016/j.jvir.2009.11.014
30. Crum WR, Hartkens T, Hill DL (2004) Non-rigid image registration: theory and practice. Br J Radiol 77(Spec No 2):S140–53
31. Kim S, Mannelli L, Hajdu CH, et al. (2006) Hepatocellular carcinoma: assessment of response to transarterial chemoembolization with image subtraction. J Magn Reson Imaging 31:348–355. doi:10.1002/jmri.22038
32. Khankan AA, Murakami T, Onishi H, et al. (2008) Hepatocellular carcinoma treated with radio frequency ablation: an early evaluation with magnetic resonance imaging. J Magn Reson Imaging 27:546–551. doi:10.1002/jmri.21050
33. Koda M, Tokunaga S, Fujise Y, et al. (2012) Assessment of ablative margin after radiofrequency ablation for hepatocellular carcinoma; comparison between magnetic resonance imaging with ferucarbotran and enhanced CT with iodized oil deposition. Eur J Radiol 81:1400–1404. doi:10.1016/j.ejrad.2011.03.004
34. Koda M, Tokunaga S, Miyoshi K, et al. (2012) Assessment of ablative margin by unenhanced magnetic resonance imaging after radiofrequency ablation for hepatocellular carcinoma. Eur J Radiol 81:2730–2736. doi:10.1016/j.ejrad.2011.11.01335
35. Mannelli L, Padia SA, Yeung RS, Green DE (2013) Irreversible electroporation of a liver metastasis. Liver Int 33:104. doi:10.1111/liv.12000
36. Zhang Y, White SB, Nicolai JR, et al. (2014) Multimodality imaging to assess immediate response to irreversible electroporation in a rat liver tumor model. Radiology 271:721–729. doi:10.1148/radiol.14130989